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ABSTRACT
A point-prevalence survey of ﬁve European university hospitals was performed to benchmark
antimicrobial drug use in order to identify potential problem areas in prescribing practice and to aid in
establishing appropriate and attainable goals. All inpatients at the university hospitals of Rijeka
(Croatia), Tartu (Estonia), Riga (Latvia), Vilnius (Lithuania) and Karolinska-Huddinge (Sweden) were
surveyed for antimicrobial drug use during a single day. The frequency of antimicrobial drug use was
24% in Rijeka, 30% in Tartu, 26% in Riga, 14% in Vilnius and 32% in Huddinge. Surgical patients were
treated with antimicrobial agents more often than medical patients in Riga (53% vs. 31%), Tartu (39%
vs. 26%) and Vilnius (54% vs. 25%). Two-thirds of patients in Rijeka, Tartu, Riga and Vilnius, and fewer
than half of the patients in Huddinge, received antimicrobial agents intravenously. Broad-spectrum
antimicrobial agents were used most commonly in Rijeka. The prevalence of nosocomial infections
treated with antibiotics was 9% at Huddinge, and 3–5% at the other centres. Benchmarking
antimicrobial drug use at ﬁve university hospitals identiﬁed differences and problem areas. The high
rates of intravenous administration, poor compliance with guidelines, and prolonged surgical
prophylaxis were general problems that deserved speciﬁc attention at all centres. A change in
prescription practices may reduce unnecessary drug use and decrease antimicrobial resistance.
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INTRODUCTION
It has been estimated that 30–50% of hospitalised
patients receive antimicrobial agents, and that up
to 50% of prescribed antimicrobial agents are not
prescribed optimally [1–4]. It has been recognised
generally that bacterial resistance is an unavoid-
able consequence of antimicrobial drug use, and
that it correlates with the overall use of antimi-
crobial drugs in a deﬁned setting [5–8]. Factors
that promote the emergence of resistance include
frequent use of broad-spectrum antimicrobial
agents, prolonged use of antimicrobial agents,
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more frequent use of invasive devices and proce-
dures, large numbers of patients with complex
medical problems in small areas within a hospital,
and the presence of patients who require pro-
longed hospitalisation and often harbour anti-
biotic-resistant bacteria [9]. The aim of the present
study was to benchmark the pattern of anti-
microbial drug use at ﬁve European university
hospitals.
MATERIALS AND METHODS
Setting
The study was carried out at ﬁve European university
hospitals of similar size in Croatia, Estonia, Latvia, Lithuania
and Sweden during the year 2003 (Table 1). The University
Hospital Rijeka (Croatia) comprises departments covering all
major specialties. Renal transplantation is performed in the
surgical department, but bone marrow, heart and liver
transplantations are not performed. The Tartu University
Hospital (Estonia) includes all major medical and surgical
specialties, including transplantations (kidney, liver and bone
marrow). The Stradins University Hospital in Riga (Latvia) is
the only referral hospital in Latvia for cardiac surgery and
renal transplantation. The Vilnius University Hospital (Lithu-
ania) includes all major specialties, except neurosurgery,
orthopaedic surgery and traumatology, infectious diseases
and obstetrics. Bone marrow, renal and heart transplanta-
tions are performed at this hospital. Tuberculosis patients are
not generally treated in this hospital. The Karolinska Uni-
versity Hospital, Huddinge (Sweden) includes all major
specialties, except neurosurgery, and has a transplantation
centre.
Guidelines for antimicrobial drug use ⁄ infection control
programmes
In Rijeka, restricted release of antimicrobial agents has been
implemented as a method to improve antimicrobial drug
use. Amikacin, carbapenems, third- and fourth-generation
cephalosporins, amoxycillin–clavulanic acid (co-amoxyclav),
glycopeptides, linezolid and piperacillin–tazobactam can be
dispensed by the hospital pharmacy only on receipt of an
order form signed by a chief physician. Recommendations for
surgical prophylaxis are provided, with cefazolin being the
main agent. While a Drug and Therapeutics Committee
(DTC) releases guidelines and recommendations for antimi-
crobial drug use, there is no formal infection control
programme. Occasional lectures are given concerning rational
antimicrobial drug use as part of continuing medical educa-
tion.
In Tartu, the restricted release antimicrobial agents include
cefazolin and cefoxitin, which may be used only for surgical
prophylaxis. The antibiotic formulary is approved by the DTC.
An infection control department is responsible for guidelines
concerning rational antimicrobial drug use. Lectures on the
rational use of antimicrobial agents are given by the infection
control doctors.
In Stradins, Riga, a restricted release list of antimicrobial
agents includes amikacin, ampicillin–sulbactam, cefepime,
ceftazidime, chloramphenicol, intravenous clindamycin,
imipenem, linezolid, meropenem, piperacillin–tazobactam,
rifampicin, intravenous trimethoprim–sulphamethoxazole
and vancomycin. These agents may be prescribed only by an
infectious disease consultant or following approval by the
medical director. In the intensive care unit, any antimicrobial
agent can be prescribed without restrictions. Guidelines for
surgical prophylaxis have been developed with the assistance
of an infectious disease consultant. The antibiotic formulary is
reviewed by the DTC at the beginning of each year. There is no
speciﬁc educational programme concerning rational antimi-
crobial drug use.
In Vilnius, a restricted release list of antimicrobial agents
includes amikacin, carbapenems, third- and fourth-generation
cephalosporins, linezolid, piperacillin–tazobactam and vanco-
mycin. These agents may only be prescribed after consulta-
tion with a clinical pharmacologist or following approval by
the medical director. Some surgical departments have their
own guidelines for surgical prophylaxis, which were devel-
oped in collaboration with a microbiologist and a clinical
pharmacologist. The hospital pharmacy supplies departments
with any drug from the recommended list. Occasional
lectures on rational antimicrobial drug use are given in some
departments.
At the Karolinska-Huddinge hospital, the DTC has formu-
lated a list of recommended antimicrobial agents for hospital
use. In addition, many clinics have their own guidelines for
treatment and prophylaxis, many of which were developed in
collaboration with a consultant in infectious diseases. There
are no restrictions on the prescription of antimicrobial agents.
Educational activities in rational antimicrobial drug use take
place within an infection control programme that began in the
year 2000 [10].
Study methodology
A modiﬁed point-prevalence study design was used; all wards
in each centre were surveyed once during one day in May
2003. The charts of all hospitalised patients who received an
antimicrobial agent (ATC codes J01 and J04, classiﬁed accord-
ing to WHO ATC ⁄DDD Index 2003) [11] were reviewed, and
the clinical data were recorded anonymously in a patient-
speciﬁc protocol [10]. The data were collected in Rijeka by
physicians during their internship, supervised by a specialist
in clinical pharmacology, in Tartu by two specialists in
infectious diseases, in Riga by an infectious disease consultant
and an infection control nurse, in Vilnius by a clinical
pharmacologist and an infection control specialist, and in
Huddinge by an infectious disease consultant ⁄hospital epide-
miologist and an infectious diseases nurse [12].
Table 1. Demographical data for theparticipatinghospitals
No. of
beds
No. of
patients
Occupancy
rate (%)
Primary catchment
area (population)
University Hospital,
Rijeka
1191 938 78.8 340 000
Tartu University Hospital 929 745 80.2 400 000
Stradins University Hospital,
Riga
1037 927 89.4 900 000
Vilnius University Hospital 1000 876 87.6 1 500 000
Karolinska University Hospital,
Huddinge
761 652 85.7 300 000
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The main purpose of antimicrobial drug use was classiﬁed
as treatment, medical or surgical prophylaxis, or unclear (with
insufﬁcient data in the medical record).
Departments were grouped as ‘medical’ (cardiology,
endocrinology, gastroenterology, haematology, infectious dis-
eases, medical admisson, neonatology, nephrology, neurology,
paediatrics, pulmonology and rheumatology), ‘surgical’
(abdominal surgery, cardiac surgery with intensive care
unit, gynaecology, neurosurgery with intensive care unit,
orthopaedics, paediatric surgery, plastic surgery, stomatolog-
ical surgery, surgical admission, endocrinology surgery, thor-
acic surgery, transplantation, urology and vascular surgery) or
‘other’ (dermatovenerology, general intensive care, paediatric
intensive care, geriatrics, obstetrics, oncology, ophthalmology,
otorhinolaryngology and rehabilitation). Tuberculosis was
treated at the department of pulmonology in Rijeka, at a
specialised department, classiﬁed as ‘other’, in Tartu, and at
medical and surgical departments in Huddinge. Tuberculosis
patients are not generally treated at Stradins hospital, Riga, or
Vilnius hospital, Lithuania.
In order to focus on the bulk (90%) of the prescriptions, the
pattern of antimicrobial drug use was presented as drug
utilisation 90% (DU90%) proﬁles [13,14]. The number of days
of hospitalisation before use of antimicrobial agents were
compared at admission, 1–2 days after admission, and >2 days
after admission. For patients who received treatment, the
frequency of consultation with infectious disease specialists
was determined at each centre, as well as whether the
indication for an antimicrobial drug was documented in the
medical record, and whether the choice of antimicrobial agent
was based on susceptibility testing. The source of infection was
categorised as hospital- or community-acquired. A hospital-
acquired infection was deﬁned as an infection that appeared
‡48 h after admission, and a community-acquired infection
was deﬁned as an infection that appeared within 48 h of
hospital admission [15]. The type of infection was classiﬁed
according to the main organ systems affected. Neither the
necessity nor appropriateness of antimicrobial drug use, nor
the correctness of the diagnoses, was evaluated in this study.
Statistical evaluation of data was performed using Statistica
v.6.0 software (StatSoft Inc., Tulsa, OK, USA). The comparisons
were made using appropriate statistical tests with a signiﬁ-
cance level of p < 0.05. The study assembled anonymous
structured data from antibiotic utilisation and infection control
programmes as part of hospital quality assessments, and did
not require ethical approval.
RESULTS
There was no signiﬁcant difference in the gender
distribution of patients among the different hos-
pitals (Pearson chi-square test, p 0.145), or in the
age (K-W ANOVA, p 0.143). Overall, 1025 of 4138
patients admitted received antimicrobial agents,
with frequencies of 24.2% in Rijeka, 30.3% in
Tartu, 25.9% in Riga, 14.4% in Vilnius and 31.6%
in Huddinge. The percentage of patients receiving
antimicrobial agents was higher in medical
departments in Rijeka and Huddinge, but higher
in surgical departments in Tartu, Riga and Vilnius
(Fig. 1). More than one antimicrobial agent was
prescribed to 21% of patients in Rijeka, 35% in
Tartu, 24% in Riga, 17% in Vilnius, and 24% in
Huddinge. The number of antimicrobial agents
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Fig. 1. The percentage of patients who received antimicrobial agents in different departments of ﬁve university hospitals.
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prescribed per patient in the centres studied did
not differ signiﬁcantly (1.2–1.6 courses ⁄patient).
The route of administration was intravenous for
60.5% patients in Rijeka, 64.5% in Tartu, 72% in
Riga, 60.5% in Vilnius, and 49% in Huddinge. In
all ﬁve centres, the majority of the patients
received antimicrobial agents for therapeutic pur-
poses. The proportion of patients with an unclear
indication for antibiotic treatment ranged from
0% in Huddinge to 29% in Riga (Table 2). Of the
prescribed agents, 90% (the DU90% proﬁle) were
accounted for by 20 antimicrobial agents (of 29
available) in Rijeka, 20 (of 27) in Huddinge, 15 (of
22) in Vilnius, 12 (of 21) in Riga, and 19 (of 31) in
Tartu (Table 3). The variations among centres, in
terms of the time between admission and com-
mencing antibiotic treatment, are summarised in
Table 4.
Consultation with an infectious disease special-
ist concerning antimicrobial treatment occurred
signiﬁcantly more frequently in Huddinge, and
least frequently in Tartu (Pearson chi-square test,
p <0.000001). Similarly, the indication for anti-
microbial administration was documented signif-
icantly more often in the medical records in
Huddinge than in the other centres (Pearson chi-
square test, p 0.000009). Susceptibility testing and
culture were also performed signiﬁcantly more
often in Huddinge than in the other hospitals
(Pearson chi-square test, p <0.001) (Table 5).
Among community-acquired infections, lower
respiratory tract infection predominated in all
centres (Rijeka 32%, Tartu 38%, Riga 23%, Vil-
nius 30%, Huddinge 27%), followed by intra-
abdominal infections in Rijeka (21%) and Riga
(23%), infections of skin and sub-mucosae in
Tartu (14%) and Vilnius (24%), and urinary tract
infections in Huddinge (20%). The frequency of
patients with nosocomial infections was 4.8% in
Table 2. Reasons for administration of antimicrobial
agents to 1025 patients in ﬁve university hospitals
Rijeka
n (%)
Tartu
n (%)
Riga
n (%)
Vilnius
n (%)
Huddinge
n (%)
Treatment 151 (67) 162 (72) 118 (49) 76 (60) 142 (69)
Surgical
prophylaxis
54 (24) 32 (14) 44 (18) 25 (20) 37 (18)
Medical
prophylaxis
18 (8) 0 (0) 8 (3) 15 (12) 27 (13)
Unclear 4 (2) 32 (14) 70 (29) 10 (8) 0 (0)
Total 227 226 240 126 206
Table 3. Distribution of prescribed antimicrobial agents (AB) accounting for 90% of all treatment courses (the DU90%
proﬁle) in ﬁve selected hospitals
Rijeka Tartu Riga Vilnius Huddinge
AB n % AB n % AB n % AB n % AB n %
Cefuroxime 41 14.0 Gentamicin 39 13.5 Cefazolin 80 26.4 Ciproﬂoxacin 18 11.8 Cefuroxime 33 12.8
Gentamicin 27 9.2 Ampicillin 29 10.1 Ciproﬂoxacin 52 17.2 Amoxycillin 16 10.5 Metronidazole 26 10.1
Metronidazole 25 8.5 Cefuroxime 28 9.7 Metronidazole 33 10.9 Cefazolin 15 9.9 Ciproﬂoxacin 22 8.5
Co-amoxyclav 22 7.5 Cefazolin 27 9.4 Ampicillin 25 8.3 Co-trimoxazole 15 9.9 Cloxacillin 16 6.2
Anti-tuberculosis
agents
20 6.8 Anti-tuberculosis
agents
24 8.3 Gentamicin 18 5.9 Cefuroxime 13 8.6 Co-trimoxazole 16 6.2
Ciproﬂoxacin 17 5.8 Ciproﬂoxacin 22 7.6 Cefuroxime 15 5.0 Metronidazole 11 7.2 Imipenem 14 5.4
Ceftriaxone 15 5.1 Metronidazole 17 5.9 Ceftriaxone 14 4.6 Ampicillin 11 7.2 Norﬂoxacin 14 5.4
Cefepime 14 4.8 Oxacillin 17 5.9 Amoxycillin 11 3.6 Penicillin G 9 5.9 Cefotaxime 12 4.7
Cefazolin 12 4.1 Penicillin G 8 2.8 Oﬂoxacin 10 3.3 Gentamicin 8 5.3 Clindamycin 12 4.7
Amoxycillin 9 3.1 Amoxycillin 7 2.4 Doxycycline 7 2.3 Vancomycin 5 3.3 Penicillin V 9 3.5
Cephalexin 8 2.7 Co-trimoxazole 7 2.4 Co-trimoxazole 6 2.0 Ceftriaxone 4 2.6 Vancomycin 8 3.1
Vancomycin 8 2.7 Cefotaxime 6 2.1 Ceftazidime 5 1.7 Cefepime 4 2.6 Penicillin G 8 3.1
Doxycycline 8 2.7 Erythromycin 6 2.1 DU90% 1–12 276 91.2 Roxithromycin 3 2.0 Amoxycillin 7 2.7
Rifampicin 8 2.7 Amikacin 5 1.7 13–21 8.8 Oxacillin 3 2.0 Flucloxacillin 7 2.7
Cefotaxime 7 2.4 Piperacillin–
tazobactam
5 1.7 Ceftazidime 2 1.3 Gentamicin 7 2.7
Meropenem 7 2.4 Cefoxitin 5 1.7 DU90% 1–15 137 90.1 Ceftazidime 6 2.3
Ceftazidime 5 1.7 Ceftazidime 4 1.4 16–22 9.9 Pivmecillinam 5 1.9
Peﬂoxacin 5 1.7 Imipenem 3 1.0 Meropenem 4 1.6
Penicillin G 5 1.7 Co-amoxyclav 3 1.0 Ampicillin 4 1.6
Clarithromycin 5 1.7 DU90% 1–19 262 90.7 Azithromycin 3 1.2
DU90% 1–20 268 91.3 20–31 9.3 DU90% 1–20 233 90.5
21–29 8.7 21–27 9.5
Table 4. Intervals between admission and commencement
of antimicrobial treatment (AB) for 1025 patients at ﬁve
centres
Start of AB
Hospital
Rijeka
(%)
Tartu
(%)
Riga
(%)
Vilnius
(%)
Huddinge
(%)
On admission 113 (49.8) 70 (31.0) 87 (36.2) 37 (29.4) 55 (26.7)
1–2 days 24 (10.6) 63 (27.9) 65 (27.1) 23 (18.2) 91 (44.2)
>2 days 90 (39.6) 93 (41.1) 88 (36.7) 66 (52.4) 60 (29.1)
Total 227 226 240 126 206
280 Clinical Microbiology and Infection, Volume 13 Number 3, March 2007
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 277–283
Rijeka (48 patients, 21% of those receiving anti-
biotics), 5.3% in Tartu (40 patients, 18% of those
receiving antibiotics), 3.0% in Riga (28 patients,
12% of those receiving antibiotics), 3.4% in
Vilnius (30 patients, 24% of those receiving
antibiotics), and 9.3% in Huddinge (61 patients,
30% of those receiving antibiotics). The most
common nosocomial infections were: urinary tract
infections (27%) and surgical site infections (20%)
in Rijeka; lower respiratory tract infections (33%),
urinary tract infections and intra-abdominal infec-
tions (13% each) in Tartu; surgical site infections
(32% and 37%, respectively) and fever of un-
known origin (25% and 23%, respectively) in
Riga and Vilnius; and fever of unknown origin
(30%), followed by sepsis (21%), in Huddinge.
The proportion of patients receiving antimicro-
bial surgical prophylaxis was 24% in Rijeka, 14%
in Tartu, 18% in Riga, 19% in Vilnius and 18% in
Huddinge (Table 2). The drugs used most com-
monly for surgical prophylaxis were: cefuroxime
(30% of patients) followed by cefazolin and
cefepime (15% and 13%, respectively) in Rijeka;
cefazolin (84%) and cefoxitin (13%) in Tartu;
cefazolin (65% and 40%, respectively) and cefu-
roxime (26% and 36%, respectively) in Riga and
Vilnius; and cefuroxime in Huddinge.
DISCUSSION
This study surveyed antimicrobial drug use in
ﬁve politically, economically and geographically
diverse countries. Antimicrobial drug use policies
in the four newly formed countries (Croatia,
Estonia, Latvia and Lithuania) were based mostly
on administrative measures and restrictions,
while at Huddinge (Sweden) the antimicrobial
drug use policy was based on recommendations
and educational activities.
In other studies reported previously, the fre-
quency of antimicrobial drug use varied between
17% and 78% of patients [16–18]. Compared with
these studies, the frequency of antimicrobial drug
use at the hospitals in the present study was not
high, even though they were tertiary referral
university centres. The number of treatment
courses per patient in the ﬁve hospitals surveyed
was similar to that in other reports [19,20]. The
lowest frequency of antimicrobial drug use (14%)
was in Vilnius; this was a reduction from a
frequency of 24% reported for 2002 (8th World
Congress on Clinical Pharmacology and Thera-
peutics, Brisbane, 2004, abstract PO 150). Several
point-prevalence studies during a single year
would probably give a more accurate picture of
the hospital’s antimicrobial drug use.
Almost one-third of the patients in Riga had
received an antimicrobial agent without a clear
indication for its use. This ﬁnding may, in part,
reﬂect differences of opinion among the investi-
gators, which was a limitation of the present
study. In the absence of clinical signs of infection,
some investigators (UD, PM) classiﬁed a duration
of antimicrobial prophylaxis of >48 h as an
unclear reason for antimicrobial therapy, while
others classiﬁed it as prophylaxis, regardless of its
appropriateness.
At Huddinge, antimicrobial agents were
administered intravenously and orally in equal
proportions, while in the low-income countries,
they were administered intravenously two-fold,
or three-fold (Riga), more often than orally. This
could not be explained simply by the severity of
disease, and may reﬂect a psychological assump-
tion that intravenous antibiotics are more effect-
ive, despite the lack of evidence to support this
general approach.
Although the hospitals in Rijeka and Riga had
similar antimicrobial policies, and the prevalence
of antimicrobial drug use was similar, the pattern
of use differed substantially. The number of
different antimicrobial agents used in Riga was
the lowest among all the hospitals surveyed.
Almost one-third of the prescribed antimicrobial
agents in Rijeka were those with restricted release,
mostly third-generation cephalosporins. Within
the DU90% in Riga, there were only two third-
generation cephalosporins listed, as restricted
release, which accounted for 6% of the treatment
courses. Although not restricted, these broad-
spectrum b-lactams were not prescribed as
Table 5. Factors associated with the prescription of
antimicrobial agents for 1025 patients admitted to ﬁve
university hospitals
Rijeka Tartu Riga Vilnius Huddinge
Consultation with IDS 7.9% 7.4% 12.7% 17.1% 50.0%
Indication for treatment
with AB in medical records
27.2% 76.5% 72.9% 90.8% 92.3%
Culture ⁄ susceptibility
testing
28.5% 26.5% 21.2% 19.7% 64.5%a
aAntimicrobial agents may have been prescribed before the results of the culture
were available, but the empirical choice was conﬁrmed by susceptibility reports and
treatment was considered as targeted.
IDS, infectious disease specialist; AB, antimicrobial agent.
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extensively in Tartu, Vilnius and Huddinge as
they were in Rijeka. In comparison, a Norwegian
study reported low use of third-generation
cephalosporins [20], while studies from the Medi-
terranean region have shown a greater proportion
of broad-spectrum antimicrobial use [21–23].
Results from the European Surveillance on Anti-
microbial Consumption (ESAC) project for out-
patient antibiotic use have shown a higher
consumption, especially of broad-spectrum anti-
microbial agents, in southern and eastern Europe
than in northern Europe [24]. The high frequency
of broad-spectrum antimicrobial prescriptions in
Rijeka could not be explained by high bacterial
resistance rates, as the percentage of patients
treated with these agents exceeded the percentage
of patients treated according to susceptibility
testing, suggesting that they were given empiric-
ally. One-half of the patients had already received
an antimicrobial agent upon admission for com-
munity-acquired infections, which raises ques-
tions about the rationality of their use. The same
pattern of antimicrobial use in Rijeka has been
described previously [25–27]. The hospitals in
Rijeka, Huddinge and Tartu had the widest range
of available antimicrobial agents and, correspond-
ingly, 90% of the patients at these centres were
treated with a wider range of agents. Interest-
ingly, little vancomycin use was recorded in Riga
and Tartu, probably because of an absence of
methicillin-resistant Staphylococcus aureus at the
time of the survey.
The ﬁnding that most patients in the surgical
departments in Vilnius, Riga and Tartu received
antimicrobial agents for treatment rather than
prophylaxis, and that most patients received an
antimicrobial agent >2 days after admission, sug-
gests a high rate of surgical site infection in these
centres. However, in Vilnius, patients are com-
monly hospitalised a few days before scheduled
elective surgery, and prophylaxis might have been
extended for >24 or 48 h, contrary to guidelines. A
retrospective review of indications for antimicro-
bial treatment in Riga showed that patients with
diagnoses such as pancreatitis, cholecystitis, cel-
lulitis and chronic ulcers are treated in surgical
departments, even if they do not need surgical
intervention. In Tartu, Vilnius and Riga, cefazolin
was the agent used most commonly for surgical
prophylaxis, which is in accord with published
guidelines [28,29]. Although not recommended as
a drug of choice for surgical prophylaxis, cefu-
roxime was used mostly for this purpose in Rijeka.
Cefuroxime is recommended for use with abdom-
inal surgery in Huddinge, but was also used for
other indications, contrary to guidelines. Cefazo-
lin was not approved for use in Sweden at the time
of this survey.
Prevalence studies are often used to provide
baseline information concerning the occurrence of
hospital infections and to help in establishing
priorities for their control. It has been estimated
that up to 10% of hospitalised patients acquire an
infection [30–32], and the prevalence of nosoco-
mial infections in the hospitals included in the
present study was within the same range.
The study has several limitations. Although the
same protocol was used in all study centres,
patients with identical diagnoses were sometimes
treated in different departments, thus giving
different reﬂections of the use of antimicrobial
agents. Interpretation of ﬁndings was also biased
in certain cases by the opinions of the local
investigator and by differences in record-keeping.
As in all other point-prevalence studies, day-by-
day and seasonal variations in antimicrobial drug
use could not be monitored. Nevertheless, this
benchmarking study, using a simple and inex-
pensive point-prevalence method, revealed sev-
eral differences in antimicrobial drug prescription
among the various centres that could indicate
potential problem areas. The high rates of intra-
venous administration, poor compliance with
published guidelines, and prolonged surgical
prophylaxis were general problems that deserve
speciﬁc attention in all centres.
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